Smartlab Europe

Dominick Arena Joins Implandata Ophthalmic Products GmbH Board of Directors as Chairman

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Norgine Invests £23m to Expand Hengoed Pharma Facility in UK

Norgine has confirmed a £23 million ($31 million) investment...

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...
- Advertisement -

Implandata Ophthalmic Products GmbH is pleased to announce that Dominick Arena is appointed as its Chairman of the Board effective immediately.

Dominick is currently an Executive Advisor for Water Street Healthcare Partners, a strategic investor focused exclusively on the healthcare industry. He brings more than 30 years experience in the medical device industry.

Max Ostermeier, CEO of Implandata states: “The entire management team is extremely pleased that Dominick is joining our Board as Chairman. We look forward to closely working with him as we enter into a new and exciting phase with Implandata.  Dominick’s operational and commercial experience will be of tremendous help as we begin the commercialization of our products. Further his M&A background will play a key role as we position the company for future strategic partnerships.”

About Implandata
Implandata is a privately held, ISO 13485 certified medical device company, which was founded in 2010 in Hannover/Germany. Implandata is a leader in the development of monitoring technologies for the treatment of Glaucoma. With the CE marked EYEMATE system, Implandata has developed the world-wide first solution for continual monitoring of intraocular pressure.

Latest stories

Related stories

Norgine Invests £23m to Expand Hengoed Pharma Facility in UK

Norgine has confirmed a £23 million ($31 million) investment...

Oral Microbiome Research and Its Implications for Future Therapeutics

Over the past decade, microbiome science has reshaped how...

Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal

Sanofi has committed up to $1.53 billion to obtain...

UK Invests £47.8M to Expand NHS Clinical Trial Capacity

The UK government has announced nearly £50 million in...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »